Cantargia AB (publ) (STO: CANTA)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.847
-0.025 (-1.34%)
Nov 19, 2024, 5:21 PM CET
-51.01%
Market Cap 335.78M
Revenue (ttm) n/a
Net Income (ttm) -193.53M
Shares Out 183.69M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 152,257
Open 1.870
Previous Close 1.872
Day's Range 1.840 - 1.870
52-Week Range 1.833 - 5.200
Beta 1.72
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2024

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 22
Stock Exchange Nasdaq Stockholm
Ticker Symbol CANTA
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.